Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

Martina Pigazzi, Elena Manara, Barbara Buldini, Valzerda Beqiri, Valeria Bisio, Claudia Tregnago, Roberto Rondelli, Riccardo Masetti, Maria Caterina Putti, Franca Fagioli, Carmelo Rizzari, Andrea Pession, Franco Locatelli, Giuseppe Basso

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e99-e101
JournalHaematologica
Volume100
Issue number3
DOIs
Publication statusPublished - 2015

Keywords

  • AIEOPt(8;21)
  • AML
  • AML1-ETORUNX1-RUNX1T1
  • CBFB-MYH11
  • Inv(16)
  • Molecular MRD
  • Pediatric
  • RQ-PCR

ASJC Scopus subject areas

  • Hematology

Cite this

Pigazzi, M., Manara, E., Buldini, B., Beqiri, V., Bisio, V., Tregnago, C., Rondelli, R., Masetti, R., Caterina Putti, M., Fagioli, F., Rizzari, C., Pession, A., Locatelli, F., & Basso, G. (2015). Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement. Haematologica, 100(3), e99-e101. https://doi.org/10.3324/haematol.2014.114579